TauRx: About Us

Bringing novel therapies and diagnostics to life for neurodegenerative diseases

KMSeng & ClaudeTauRx was co-founded in 2002 by Professor Claude M. Wischik, CEO, and the late Dr K.M. Seng of Singapore, a visionary venture capitalist and physician.  TauRx is a spin-out company of the University of Aberdeen, UK.  Using world-class-proprietary drug discovery platforms, the company aims to halt the progression of Alzheimer’s, frontotemporal dementia (FTD) and other neurodegenerative diseases with innovative treatments and diagnostics.

The company’s novel Tau Aggregation Inhibitors (TAIs) target the formation (aggregation) of Tau protein ‘tangles’ in the brain.  These Tau tangles have been correlated with dementia and develop in the brain up to 20 years before symptoms associated with dementia develop.  TAIs work by dissolving the Tau tangles and preventing them from forming.

TauRx’s second-generation TAI, LMTX™, is patented for the treatment and prevention of Alzheimer’s.  This product is now in Phase 3 clinical trials and the clinical trial programme is being conducted in over 20 countries and involves 1,700 patients worldwide.  TauRx plans to announce results of these trials during 2016. 

In 2008 the company presented the results of a large Phase 2 clinical trial involving 321 patients with mild and moderate Alzheimer’s.  This study was conducted in the UK and Singapore. It involved the first-generation TAI, rember®.  The results were reported at the Alzheimer’s Association International Conference on Alzheimer's Disease Conference in 2008 (ICAD 2008) in Chicago, USA.  These results showed that the rate of Alzheimer’s progression was reduced by 90% over a 2-year period.  (See Clinical Research for additional information.)

TauRx researchers are currently developing diagnostic ligands for use in brain scans to measure the build-up of Tau tangles so patients can be diagnosed early and treatment can be started before permanent damage progresses.  TauRx has also determined that its TAIs show activity on the synuclein fibres which accumulate in the brains of people with Parkinson’s disease in the form of Lewy bodies.

Currently the company has primary research facilities located at the University of Aberdeen in Scotland and undertakes collaborative research with institutes in Berlin and Warsaw.

Liberty Building_Aberdeen HQ

What Next?

  • Explore this section to learn more about TauRx as a company and our leadership.

TauRx Publishes Six New Journal Articles

TauRx Completes Recruitment to Phase 3 Alzheimer’s Disease Studies